Amgen plans launch of blockbusters' biosimilars in 4 years

02/8/2013 | Reuters

Amgen intends to commercialize biosimilar versions of six of the biggest-selling biologic drugs including Humira and Remicade, the main rivals of its own rheumatoid arthritis treatment Enbrel, starting in 2017, CEO Robert Bradway said. The biotech firm sees biosimilars as a multi-billion dollar opportunity, and it expects to become a major player in the market once the approval pathway is finalized.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY